ClinicalTrials.gg
CompletedNCT04607837GLADIATOR UCUpdated Jul 15, 2025Results posted

Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

A Phase 2 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Pfizer. Completed at 288 sites in 18 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Enrollment
6th of 12
234 · median 195
Started
2021
with 1 other
Phase 2
6 of 12
2 open now
Registered
7th of 12
by date
Lead sponsor
6 of 12
Pfizer

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 2, and was the 7th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative colitis
  • Etrasimod
  • APD334
  • UC
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Ulcerative Colitis (UC) ≥ 3 months prior to screening
  • Active UC confirmed by endoscopy
  • Moderately active UC defined as a modified Mayo score of 4 to 6 and an endoscopic score ≥ 2 and rectal bleeding score ≥ 1
  • Received a surveillance colonoscopy within 12 months before baseline

Exclusion criteria

Exclusion Criteria:

  • Severe extensive colitis
  • Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a fistula consistent with Crohn's disease
  • Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
  • Hospitalization for exacerbation of UC requiring intravenous within 12 weeks prior to or after screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    Etrasimod 2 mg

    Drug: Etrasimod

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment

    Also known as: APD334

  • DrugPlacebo

    Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS)

    MMS is used to assess disease activity in participants with UC and has following components: endoscopic score(ES),rectal bleeding(RB),stool frequency(SF).Each component score ranges from 0 to 3(0=normal,1=mild,2=moderate,3=severe); higher scores indicating more severe disease.ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,scores ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding, ulceration\]).RB reported most severe amount of blood passed per rectum in 24-hour period,scores ranged from 0(no blood seen) to 3(blood alone passes).SF reported number of stools in 24-hour period relative to normal number of stools for that participant in same period,scores ranged from 0(normal number of stools) to 3(5 or more stools than normal).CR per FDA draft guidance defined as:SF=0 or 1 and no greater than baseline, RB=0,ES less than or equal to (\<=)1(excluding friability).Percentage of participants achieving CR at Week 52 was evaluated.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving Clinical Remission at Week 12 Using MMS

    MMS is used to assess disease activity in participants with UC and has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe); higher scores indicating more severe disease. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]). RB reported the most severe amount of blood passed per rectum in a 24-hour period, scores ranged from 0 (no blood seen) to 3 (blood alone passes). SF reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal). CR per FDA draft guidance was defined as: SF=0 or =1 and no greater than baseline, RB=0, and ES \<=1 (excluding friability). Percentage of participants achieving CR at Week 12 was evaluated in this endpoint.

    Time frame: Week 12

  2. Percentage of Participants Achieving Endoscopic Improvement at Week 52

    Endoscopic improvement was defined as ES \<=1 (excluding friability). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. Percentage of participants achieving endoscopic improvement at Week 52 was evaluated in this endpoint.

    Time frame: Week 52

  3. Percentage of Participants Achieving Symptomatic Remission at Week 52

    Symptomatic remission was defined as SF =0 (or = 1 with a \>= 1 point decrease from baseline) and RB =0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, scores ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. Percentage of participants achieving symptomatic remission at Week 52 was evaluated in this endpoint.

    Time frame: Week 52

  4. Percentage of Participants Achieving Complete Symptomatic Remission at Week 52

    Complete symptomatic remission was defined as participants with RB = 0 and SF = 0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, scores ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. Percentage of participants achieving complete symptomatic remission at Week 52 was evaluated in this endpoint.

    Time frame: Week 52

  5. Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 52

    Histologic-endoscopic mucosal improvement was defined as ES \<=1 (excluding friability) with Geboes score \<2.0. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. The Geboes score grading system was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Percentage of participants achieving mucosal improvement at Week 52 was evaluated in this endpoint.

    Time frame: Week 52

  6. Percentage of Participants Achieving Clinical Remission at Both Weeks 12 and 52 [Combined] Using MMS

    MMS is used to assess disease activity in participants with UC and has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0= normal, 1= mild, 2= moderate, 3= severe); higher scores = more severe disease. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease). RB: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes). SF reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal). Clinical remission per FDA draft guidance: SF =0 or =1 and no greater than baseline, RB =0, and ES \<=1 (excluding friability). Percentage of participants who achieved clinical remission at both the time points Week 12 and Week 52 \[Combined\] are reported.

    Time frame: Weeks 12 and 52 [Combined]

  7. Percentage of Participants With 12-Week Corticosteroid-Free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline Using MMS

    MMS has following components:ES, RB and SF. Each component score ranges from 0 to 3(0=normal,1=mild,2=moderate,3=severe); higher scores indicating more severe disease. ES:worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0(normal or inactive disease)to 3(severe disease). RB:most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0(no blood seen)to 3(blood alone passes). SF:number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0(normal number of stools)to 3(5 or more stools than normal). CR per FDA draft guidance as: SF =0 or =1 and no greater than baseline, RB=0, and ES \<=1(excluding friability). 12-week corticosteroid-free CR was defined as CR at Week 52 and corticosteroid-free for \>=12 weeks immediately prior to Week 52. The baseline was balanced between treatment groups and representative of participants with mildly to moderately active UC.

    Time frame: Week 52

  8. Percentage of Participants With 12-Week Corticosteroid-Free Clinical Remission at Week 52 Using MMS

    MMS has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0=normal,1=mild,2=moderate,3=severe); higher scores indicating more severe disease. ES: worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0(normal or inactive disease) to 3 (severe disease). RB: most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0(no blood seen) to 3 (blood alone passes). SF: number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0(normal number of stools) to 3 (5 or more stools than normal). CR per FDA draft guidance as: SF =0 or =1 and no greater than baseline, RB=0, and ES \<=1(excluding friability). 12-week corticosteroid-free CR was defined as CR at Week 52 and corticosteroid-free for \>=12 weeks immediately prior to Week 52.

    Time frame: Week 52

  9. Percentage of Participants Achieving 4-Week Corticosteroid-Free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline Using MMS

    MMS has following components: ES, RB and SF; each ranged as 0=normal,1=mild,2=moderate,3=severe; total MMS score 0-9; higher scores=more severe disease. ES:worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0(normal or inactive disease)to 3(severe disease). RB:most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0(no blood seen) to 3(blood alone passes). SF:number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0(normal number of stools)to 3(5 or more stools than normal). CR per FDA draft guidance as: SF =0 or =1 and no greater than baseline, RB=0, and ES \<=1(excluding friability). 4-week corticosteroid-free CR was defined as CR at Week 52 and corticosteroid-free for \>=4 weeks immediately prior to Week 52. The baseline was balanced between treatment groups and representative of participants with mildly to moderately active UC.

    Time frame: Week 52

  10. Percentage of Participants With 4-Week Corticosteroid-Free Clinical Remission at Week 52 Using MMS

    MMS has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0=normal,1=mild,2=moderate,3=severe); where total score is sum of three components giving total MMS score as 0 to 9; higher scores indicating more severe disease. ES: worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0(normal or inactive disease) to 3 (severe disease). RB: most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0(no blood seen) to 3 (blood alone passes). SF: number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal). CR per FDA draft guidance as: SF =0 or =1 and no greater than baseline, RB=0, and ES \<=1(excluding friability). 4-week corticosteroid-free CR was defined as CR at Week 52 and corticosteroid-free for \>=4 weeks immediately prior to Week 52.

    Time frame: Week 52

  11. Percentage of Participants Achieving Clinical Response at Week 12 Using MMS

    Clinical response was defined as a \>=2-point and \>=30 percentage (%) decrease from baseline in MMS, and a \>=1-point decrease from baseline in RB subscore or an absolute RB subscore \<=1 and is as per FDA draft guidance. MMS was used to assess disease activity in participants with UC and has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0= normal, 1= mild, 2= moderate, 3= severe); where total score is sum of three components giving total MMS score as 0 to 9; higher scores indicating more severe disease. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]). Percentage of participants achieving clinical response at Week 12 was evaluated in this endpoint.

    Time frame: Week 12

  12. Percentage of Participants Achieving Clinical Response at Week 52 Using MMS

    Clinical response was defined as a \>=2-point and \>=30 % decrease from baseline in MMS, and a \>=1-point decrease from baseline in RB subscore or an absolute RB subscore \<=1 and is as per FDA draft guidance. MMS is used to assess disease activity in participants with UC and has following components: ES, RB and SF. Each component scores ranges from 0 to 3 (0= normal, 1= mild, 2= moderate, 3= severe); where total score is sum of three components giving total MMS score as 0 to 9; higher scores indicating more severe disease. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]). Percentage of participants achieving clinical response at Week 52 was evaluated in this endpoint.

    Time frame: Week 52

  13. Percentage of Participants Achieving Endoscopic Improvement at Week 12

    Endoscopic improvement was defined as ES \<=1 (excluding friability). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. Percentage of participants achieving endoscopic improvement at Week 12 was evaluated in this endpoint.

    Time frame: Week 12

  14. Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 12

    Histologic-endoscopic mucosal improvement was defined as ES \<=1 (excluding friability) with Geboes score \<2.0. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. The Geboes score grading system was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Percentage of participants achieving mucosal improvement at Week 12 was evaluated in this endpoint.

    Time frame: Week 12

  15. Percentage of Participants Achieving Symptomatic Remission at Week 12

    Symptomatic remission was defined as SF =0 (or = 1 with a \>= 1 point decrease from baseline) and RB =0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, scores ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, scores ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. Percentage of participants achieving symptomatic remission at Week 12 was evaluated in this endpoint.

    Time frame: Week 12

  16. Percentage of Participants Achieving Complete Symptomatic Remission at Week 12

    Complete symptomatic remission was defined as participants with RB = 0 and SF = 0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, scores ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, scores ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. Percentage of participants achieving complete symptomatic remission at Week 12 was evaluated in this endpoint.

    Time frame: Week 12

  17. Percentage of Participants Achieving Change From Baseline in Both ES and RB or in Both ES and SF at Week 12

    ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. RB: reported the most severe amount of blood passed per rectum in a 24-hour period, scores ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. SF reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. Percentage of participants with reduction from baseline in both ES and RB or in both ES and SF at Week 12 was evaluated in this endpoint. The baseline primary analysis set was balanced between treatment groups and representative of participants with mildly to moderately active UC.

    Time frame: Baseline to Week 12

  18. Percentage of Participants Achieving Histologic Response Based on the Geboes Grading System at Week 12

    Histologic response based on the Geboes grading system was defined as Geboes score \<=3.1. The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Percentage of participants achieving histologic response based on the Geboes grading system at week 12 was evaluated in this endpoint.

    Time frame: Week 12

  19. Percentage of Participants Achieving Histologic Response Based on Robarts Histopathology Index (RHI) at Week 12

    RHI is an evaluative index, derived from the Geboes score, that is designed to be reproducible and responsive to clinically meaningful change in disease activity over time. Histologic response based on RHI was defined as decrease in RHI of \>=7 points from baseline. Total RHI score ranges from 0 (no disease activity) to 33 (severe disease activity), higher score = more severity. Percentage of participants achieving histologic response based on RHI at Week 12 was evaluated in this endpoint.

    Time frame: Week 12

Other outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and all non-SAEs.

    Time frame: From first dose of study treatment up to 4 weeks post last dose of study treatment (up to 56 Weeks)

  2. Number of Participants With AEs Based on Severity

    An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE was therefore any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity was classified using common terminology criteria for adverse events (CTCAE), version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to AE. Only those categories in which at least 1 participant had data for any reporting group were reported.

    Time frame: From first dose of study treatment up to 4 weeks post last dose of study treatment (up to 56 Weeks)

07

Results

Posted Jul 15, 2025

Participant flow

Participant flow — Overall Study
MilestoneEtrasimodPlacebo
Started15579
Safety set15479
Primary analysis set12760
Completed9734
Not completed5845
Withdrew: Adverse event82
Withdrew: Withdrawal by subject87
Withdrew: Physician decision20
Withdrew: Lack of efficacy20
Withdrew: Participant terminated by sponsor10
Withdrew: Disease worsening3636
Withdrew: Other10

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS)

MMS is used to assess disease activity in participants with UC and has following components: endoscopic score(ES),rectal bleeding(RB),stool frequency(SF).Each component score ranges from 0 to 3(0=normal,1=mild,2=moderate,3=severe); higher scores indicating more severe disease.ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,scores ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding, ulceration\]).RB reported most severe amount of blood passed per rectum in 24-hour period,scores ranged from 0(no blood seen) to 3(blood alone passes).SF reported number of stools in 24-hour period relative to normal number of stools for that participant in same period,scores ranged from 0(normal number of stools) to 3(5 or more stools than normal).CR per FDA draft guidance defined as:SF=0 or 1 and no greater than baseline, RB=0,ES less than or equal to (\<=)1(excluding friability).Percentage of participants achieving CR at Week 52 was evaluated.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS)
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS)26.018.3
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.2524 · Risk difference (rd): 7.35 · 95% CI -5.24 to 19.94
SecondaryPercentage of Participants Achieving Clinical Remission at Week 12 Using MMS

MMS is used to assess disease activity in participants with UC and has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe); higher scores indicating more severe disease. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]). RB reported the most severe amount of blood passed per rectum in a 24-hour period, scores ranged from 0 (no blood seen) to 3 (blood alone passes). SF reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal). CR per FDA draft guidance was defined as: SF=0 or =1 and no greater than baseline, RB=0, and ES \<=1 (excluding friability). Percentage of participants achieving CR at Week 12 was evaluated in this endpoint.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 12 Using MMS
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Clinical Remission at Week 12 Using MMS28.311.7
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.0068 · Risk difference (rd): 15.61 · 95% CI 4.31 to 26.91
SecondaryPercentage of Participants Achieving Endoscopic Improvement at Week 52

Endoscopic improvement was defined as ES \<=1 (excluding friability). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. Percentage of participants achieving endoscopic improvement at Week 52 was evaluated in this endpoint.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Improvement at Week 52
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Endoscopic Improvement at Week 5232.323.3
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.2302 · Risk difference (rd): 8.24 · 95% CI -5.22 to 21.71
SecondaryPercentage of Participants Achieving Symptomatic Remission at Week 52

Symptomatic remission was defined as SF =0 (or = 1 with a \>= 1 point decrease from baseline) and RB =0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, scores ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. Percentage of participants achieving symptomatic remission at Week 52 was evaluated in this endpoint.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission at Week 52
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Symptomatic Remission at Week 5237.030.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.3339 · Risk difference (rd): 7.12 · 95% CI -7.32 to 21.55
SecondaryPercentage of Participants Achieving Complete Symptomatic Remission at Week 52

Complete symptomatic remission was defined as participants with RB = 0 and SF = 0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, scores ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. Percentage of participants achieving complete symptomatic remission at Week 52 was evaluated in this endpoint.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Complete Symptomatic Remission at Week 52
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Complete Symptomatic Remission at Week 5220.520.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.9141 · Risk difference (rd): 0.68 · 95% CI -11.76 to 13.13
SecondaryPercentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 52

Histologic-endoscopic mucosal improvement was defined as ES \<=1 (excluding friability) with Geboes score \<2.0. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. The Geboes score grading system was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Percentage of participants achieving mucosal improvement at Week 52 was evaluated in this endpoint.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 52
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 5225.215.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.1089 · Risk difference (rd): 9.56 · 95% CI -2.13 to 21.25
SecondaryPercentage of Participants Achieving Clinical Remission at Both Weeks 12 and 52 [Combined] Using MMS

MMS is used to assess disease activity in participants with UC and has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0= normal, 1= mild, 2= moderate, 3= severe); higher scores = more severe disease. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease). RB: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes). SF reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal). Clinical remission per FDA draft guidance: SF =0 or =1 and no greater than baseline, RB =0, and ES \<=1 (excluding friability). Percentage of participants who achieved clinical remission at both the time points Week 12 and Week 52 \[Combined\] are reported.

Time frame:
Weeks 12 and 52 [Combined]
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission at Both Weeks 12 and 52 [Combined] Using MMS
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Clinical Remission at Both Weeks 12 and 52 [Combined] Using MMS16.55.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.0104 · Risk difference (rd): 11.19 · 95% CI 2.63 to 19.75
SecondaryPercentage of Participants With 12-Week Corticosteroid-Free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline Using MMS

MMS has following components:ES, RB and SF. Each component score ranges from 0 to 3(0=normal,1=mild,2=moderate,3=severe); higher scores indicating more severe disease. ES:worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0(normal or inactive disease)to 3(severe disease). RB:most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0(no blood seen)to 3(blood alone passes). SF:number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0(normal number of stools)to 3(5 or more stools than normal). CR per FDA draft guidance as: SF =0 or =1 and no greater than baseline, RB=0, and ES \<=1(excluding friability). 12-week corticosteroid-free CR was defined as CR at Week 52 and corticosteroid-free for \>=12 weeks immediately prior to Week 52. The baseline was balanced between treatment groups and representative of participants with mildly to moderately active UC.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With 12-Week Corticosteroid-Free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline Using MMS
Percentage of participantsEtrasimodPlacebo
Percentage of Participants With 12-Week Corticosteroid-Free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline Using MMS16.216.7
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.9203 · Risk difference (rd): -1.07 · 95% CI -22.06 to 19.92
SecondaryPercentage of Participants With 12-Week Corticosteroid-Free Clinical Remission at Week 52 Using MMS

MMS has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0=normal,1=mild,2=moderate,3=severe); higher scores indicating more severe disease. ES: worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0(normal or inactive disease) to 3 (severe disease). RB: most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0(no blood seen) to 3 (blood alone passes). SF: number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0(normal number of stools) to 3 (5 or more stools than normal). CR per FDA draft guidance as: SF =0 or =1 and no greater than baseline, RB=0, and ES \<=1(excluding friability). 12-week corticosteroid-free CR was defined as CR at Week 52 and corticosteroid-free for \>=12 weeks immediately prior to Week 52.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With 12-Week Corticosteroid-Free Clinical Remission at Week 52 Using MMS
Percentage of participantsEtrasimodPlacebo
Percentage of Participants With 12-Week Corticosteroid-Free Clinical Remission at Week 52 Using MMS25.216.7
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.1726 · Risk difference (rd): 8.49 · 95% CI -3.71 to 20.68
SecondaryPercentage of Participants Achieving 4-Week Corticosteroid-Free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline Using MMS

MMS has following components: ES, RB and SF; each ranged as 0=normal,1=mild,2=moderate,3=severe; total MMS score 0-9; higher scores=more severe disease. ES:worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0(normal or inactive disease)to 3(severe disease). RB:most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0(no blood seen) to 3(blood alone passes). SF:number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0(normal number of stools)to 3(5 or more stools than normal). CR per FDA draft guidance as: SF =0 or =1 and no greater than baseline, RB=0, and ES \<=1(excluding friability). 4-week corticosteroid-free CR was defined as CR at Week 52 and corticosteroid-free for \>=4 weeks immediately prior to Week 52. The baseline was balanced between treatment groups and representative of participants with mildly to moderately active UC.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 4-Week Corticosteroid-Free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline Using MMS
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving 4-Week Corticosteroid-Free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline Using MMS30.030.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.9272 · Risk difference (rd): -1.71 · 95% CI -38.31 to 34.90
SecondaryPercentage of Participants With 4-Week Corticosteroid-Free Clinical Remission at Week 52 Using MMS

MMS has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0=normal,1=mild,2=moderate,3=severe); where total score is sum of three components giving total MMS score as 0 to 9; higher scores indicating more severe disease. ES: worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0(normal or inactive disease) to 3 (severe disease). RB: most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0(no blood seen) to 3 (blood alone passes). SF: number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal). CR per FDA draft guidance as: SF =0 or =1 and no greater than baseline, RB=0, and ES \<=1(excluding friability). 4-week corticosteroid-free CR was defined as CR at Week 52 and corticosteroid-free for \>=4 weeks immediately prior to Week 52.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-Week Corticosteroid-Free Clinical Remission at Week 52 Using MMS
Percentage of participantsEtrasimodPlacebo
Percentage of Participants With 4-Week Corticosteroid-Free Clinical Remission at Week 52 Using MMS25.216.7
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.1726 · Risk difference (rd): 8.49 · 95% CI -3.71 to 20.68
SecondaryPercentage of Participants Achieving Clinical Response at Week 12 Using MMS

Clinical response was defined as a \>=2-point and \>=30 percentage (%) decrease from baseline in MMS, and a \>=1-point decrease from baseline in RB subscore or an absolute RB subscore \<=1 and is as per FDA draft guidance. MMS was used to assess disease activity in participants with UC and has following components: ES, RB and SF. Each component score ranges from 0 to 3 (0= normal, 1= mild, 2= moderate, 3= severe); where total score is sum of three components giving total MMS score as 0 to 9; higher scores indicating more severe disease. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]). Percentage of participants achieving clinical response at Week 12 was evaluated in this endpoint.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Response at Week 12 Using MMS
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Clinical Response at Week 12 Using MMS55.936.7
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.0151 · Risk difference (rd): 18.64 · 95% CI 3.61 to 33.67
SecondaryPercentage of Participants Achieving Clinical Response at Week 52 Using MMS

Clinical response was defined as a \>=2-point and \>=30 % decrease from baseline in MMS, and a \>=1-point decrease from baseline in RB subscore or an absolute RB subscore \<=1 and is as per FDA draft guidance. MMS is used to assess disease activity in participants with UC and has following components: ES, RB and SF. Each component scores ranges from 0 to 3 (0= normal, 1= mild, 2= moderate, 3= severe); where total score is sum of three components giving total MMS score as 0 to 9; higher scores indicating more severe disease. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]). Percentage of participants achieving clinical response at Week 52 was evaluated in this endpoint.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Response at Week 52 Using MMS
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Clinical Response at Week 52 Using MMS44.138.3
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.4419 · Risk difference (rd): 5.96 · 95% CI -9.22 to 21.13
SecondaryPercentage of Participants Achieving Endoscopic Improvement at Week 12

Endoscopic improvement was defined as ES \<=1 (excluding friability). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. Percentage of participants achieving endoscopic improvement at Week 12 was evaluated in this endpoint.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Improvement at Week 12
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Endoscopic Improvement at Week 1244.120.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.0007 · Risk difference (rd): 23.33 · 95% CI 9.78 to 36.89
SecondaryPercentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 12

Histologic-endoscopic mucosal improvement was defined as ES \<=1 (excluding friability) with Geboes score \<2.0. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. The Geboes score grading system was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Percentage of participants achieving mucosal improvement at Week 12 was evaluated in this endpoint.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 12
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 1229.113.3
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.0128 · Risk difference (rd): 14.99 · 95% CI 3.19 to 26.79
SecondaryPercentage of Participants Achieving Symptomatic Remission at Week 12

Symptomatic remission was defined as SF =0 (or = 1 with a \>= 1 point decrease from baseline) and RB =0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, scores ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, scores ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. Percentage of participants achieving symptomatic remission at Week 12 was evaluated in this endpoint.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission at Week 12
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Symptomatic Remission at Week 1236.225.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.1492 · Risk difference (rd): 10.24 · 95% CI -3.67 to 24.14
SecondaryPercentage of Participants Achieving Complete Symptomatic Remission at Week 12

Complete symptomatic remission was defined as participants with RB = 0 and SF = 0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, scores ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, scores ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. Percentage of participants achieving complete symptomatic remission at Week 12 was evaluated in this endpoint.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Complete Symptomatic Remission at Week 12
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Complete Symptomatic Remission at Week 1220.520.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.9774 · Risk difference (rd): 0.18 · 95% CI -12.18 to 12.53
SecondaryPercentage of Participants Achieving Change From Baseline in Both ES and RB or in Both ES and SF at Week 12

ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, scores ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. RB: reported the most severe amount of blood passed per rectum in a 24-hour period, scores ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. SF reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. Percentage of participants with reduction from baseline in both ES and RB or in both ES and SF at Week 12 was evaluated in this endpoint. The baseline primary analysis set was balanced between treatment groups and representative of participants with mildly to moderately active UC.

Time frame:
Baseline to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Change From Baseline in Both ES and RB or in Both ES and SF at Week 12
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Change From Baseline in Both ES and RB or in Both ES and SF at Week 1244.921.7
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.0011 · Risk difference (rd): 22.83 · 95% CI 9.17 to 36.49
SecondaryPercentage of Participants Achieving Histologic Response Based on the Geboes Grading System at Week 12

Histologic response based on the Geboes grading system was defined as Geboes score \<=3.1. The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Percentage of participants achieving histologic response based on the Geboes grading system at week 12 was evaluated in this endpoint.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Histologic Response Based on the Geboes Grading System at Week 12
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Histologic Response Based on the Geboes Grading System at Week 1244.933.3
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.1513 · Risk difference (rd): 10.8 · 95% CI -3.95 to 25.56
SecondaryPercentage of Participants Achieving Histologic Response Based on Robarts Histopathology Index (RHI) at Week 12

RHI is an evaluative index, derived from the Geboes score, that is designed to be reproducible and responsive to clinically meaningful change in disease activity over time. Histologic response based on RHI was defined as decrease in RHI of \>=7 points from baseline. Total RHI score ranges from 0 (no disease activity) to 33 (severe disease activity), higher score = more severity. Percentage of participants achieving histologic response based on RHI at Week 12 was evaluated in this endpoint.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Histologic Response Based on Robarts Histopathology Index (RHI) at Week 12
Percentage of participantsEtrasimodPlacebo
Percentage of Participants Achieving Histologic Response Based on Robarts Histopathology Index (RHI) at Week 1246.535.0
Statistical analysis
  • Etrasimod vs Placebo · Mantel Haenszel · p = 0.1823 · Risk difference (rd): 10.07 · 95% CI -4.73 to 24.87
Other pre-specifiedNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect. AEs included both SAEs and all non-SAEs.

Time frame:
From first dose of study treatment up to 4 weeks post last dose of study treatment (up to 56 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsEtrasimodPlacebo
Number of Participants With Adverse Events (AEs)10149
Other pre-specifiedNumber of Participants With AEs Based on Severity

An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE was therefore any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity was classified using common terminology criteria for adverse events (CTCAE), version 5.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to AE. Only those categories in which at least 1 participant had data for any reporting group were reported.

Time frame:
From first dose of study treatment up to 4 weeks post last dose of study treatment (up to 56 Weeks)
Reported as:
Count of participants · Participants
Number of Participants With AEs Based on Severity
ParticipantsEtrasimodPlacebo
Grade 14823
Grade 24224
Grade 3112

Adverse events

Collected over From first dose of study treatment up to 4 weeks post last dose of study treatment (up to 56 Weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etrasimod0/154 (0%)10/154 (6.5%)100/154 (64.9%)
Placebo0/79 (0%)1/79 (1.3%)48/79 (60.8%)
Most frequent serious events
Most frequent serious events
EventEtrasimodPlacebo
Colitis ulcerativeGastrointestinal disorders4/1540/79
AngioedemaSkin and subcutaneous tissue disorders0/1541/79
Chest painGeneral disorders1/1540/79
CholelithiasisHepatobiliary disorders1/1540/79
Post procedural infectionInfections and infestations1/1540/79
Viral infectionInfections and infestations1/1540/79
Incisional herniaInjury, poisoning and procedural complications1/1540/79
Radius fractureInjury, poisoning and procedural complications1/1540/79
Ulna fractureInjury, poisoning and procedural complications1/1540/79
EpilepsyNervous system disorders1/1540/79
Most frequent other events
Showing 10 of 191
Most frequent other events
EventEtrasimodPlacebo
Colitis ulcerativeGastrointestinal disorders19/1548/79
COVID-19Infections and infestations15/1547/79
Alanine aminotransferase increasedInvestigations13/1541/79
Gamma-glutamyltransferase increasedInvestigations13/1542/79
AnaemiaBlood and lymphatic system disorders4/1546/79
HeadacheNervous system disorders9/1543/79
Aspartate aminotransferase increasedInvestigations8/1541/79
Blood triglycerides increasedInvestigations8/1541/79
Upper respiratory tract infectionInfections and infestations3/1544/79
Abdominal painGastrointestinal disorders4/1543/79

Baseline characteristics

Safety set included all randomized participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(Years)EtrasimodPlaceboTotal
Mean41.6 ± 13.1540.8 ± 13.0041.3 ± 13.08
Sex: Female, Male
Sex: Female, Male(Participants)EtrasimodPlaceboTotal
Female6340103
Male9139130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EtrasimodPlaceboTotal
Hispanic or Latino6612
Not Hispanic or Latino14673219
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EtrasimodPlaceboTotal
American Indian or Alaska Native000
Asian8715
Native Hawaiian or Other Pacific Islander000
Black or African American213
White14367210
More than one race000
Unknown or Not Reported145
08

Study locations

288 sites
  • Center for Digestive Health (Colonoscopy Location)
    Dothan, Alabama 36301, United States
  • Digestive Health Specialists
    Dothan, Alabama 36301, United States
  • Dothan Eyecare-Dr. Brent McKinley (OCT Location)
    Dothan, Alabama 36301, United States
  • Pulmonary Associates (Secondary PFT Location)
    Dothan, Alabama 36301, United States
  • Flowers Hospital (PFT Location)
    Dothan, Alabama 36305, United States
  • Arizona Retina Institute/ Phoenix Retina Associates(OCT)
    Peoria, Arizona 85381, United States
  • SimonMed Imaging (Imaging)
    Peoria, Arizona 85381, United States
  • Sun City Endoscopy (Endoscopy)
    Sun City, Arizona 85351, United States
  • Euclid Endoscopy Center-El Cajon (Endoscopy procedure only)
    El Cajon, California 92020, United States
  • Center for Clinical Research (CCR)
    Irvine, California 92697, United States
  • UCI Gavin Herbert Eye Institute
    Irvine, California 92697, United States
  • UCI Gottschalk Medical Plaza
    Irvine, California 92697, United States
  • Dr. Raed Al-Naser -Sharp Grossmont outpatient (DLCO procedure only)
    La Mesa, California 91942, United States
  • Dr. Sally s. Lee in La Mesa (Ophthalmologist procedure only)
    La Mesa, California 91942, United States
  • Advanced Endoscopy and Pain Center (Colonoscopy)
    Lancaster, California 93534, United States
  • Advanced Imaging Center (Chest X-Ray)
    Lancaster, California 93534, United States
  • Antelope Valley Eye Care (Ophthalmologist)
    Lancaster, California 93534, United States
  • AV Pediatrics, Allergy and Family Medicine (PFT, Physical Exam, ECG Review, Lab Review)
    Lancaster, California 93534, United States
  • Jatinder S. Pruthi, MD FACG CPI (Physical Exam, ECG Review, Lab Review)
    Lancaster, California 93534, United States
  • OM Research LLC
    Lancaster, California 93534, United States
  • Abraham M. lshaaya MD (X-Ray)
    Los Angeles, California 90036, United States
  • Entertainment Medical Group, Inc (Main Site, Subject Visits, IP Delivery/Storage, Regulatory,
    Los Angeles, California 90036, United States
  • Advanced Vision Care (OCT)
    Los Angeles, California 90067, United States
  • Century City Endoscopy (Colonoscopy - Nicholas Karyotakis M.D. Endoscopist)
    Los Angeles, California 90067, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC
    Los Angeles, California 90067, United States
  • United Surgery Center Murrieta [Endoscopy Only]
    Murrieta, California 92562, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • CCR-ICTS Center for Innovative Patient Care
    Orange, California 92697, United States
  • UCI Health Eye Care Services (Ophthalmoscopy and OCTs)
    Orange, California 92868, United States
  • UCI Health H. H. Chao Comprehensive Digestive Disease Center
    Orange, California 92868, United States
  • UCI Investigational Drug Services (IDSP - Pharmacy)
    Orange, California 92868, United States
  • UCI Irvine Medical Center - Pulmonology Services - PFTs
    Orange, California 92868, United States
  • ACRC Studies
    San Diego, California 92119, United States
  • California Eye Professionals [OCT Only]
    Temecula, California 92591, United States
  • United Surgery Center Temecula [Endoscopy Only]
    Temecula, California 92592, United States
  • Front Range Endoscopy Center
    Colorado Springs, Colorado 80903, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Colorado Springs Pulmonary Consultants, PC
    Colorado Springs, Colorado 80909, United States
  • The Wright Eye Center (OCT Facility)
    Colorado Springs, Colorado 80909, United States
  • Colorado Springs Imaging
    Colorado Springs, Colorado 80919, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80920, United States
  • Florida Advanced Gastroenterology Center - Rahman Nakshabendi MD and Imad Nakshabendi, MD
    Brandon, Florida 33511, United States
  • Bay Area Chest Physicians, P.A.,-(Pulmonary Function Test)
    Clearwater, Florida 33756, United States
  • GASTRO FLORIDA (ADMINISTRATIVE DUTIES etc. CRA visits)
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy (Colonoscopy Procedures)
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy Center (Endoscopy Procedures)
    Clearwater, Florida 33756, United States
  • West Coast Radiology (Chest X-ray)
    Clearwater, Florida 33756, United States
  • Northwood Vision- Optical Coherence Tomography (OCT)
    Clearwater, Florida 33761, United States
  • Beraja Medical Institute (OCT)
    Coral Gables, Florida 33134, United States
  • Juan Barrio, MD (PFT when needed)
    Coral Gables, Florida 33134, United States
  • The Endoscopy Center (Endoscopy Procedure)
    Miami, Florida 33134, United States
  • Research Associates of South Florida
    Miami, Florida 33156, United States
  • Kendall Endoscopy and Surgery Center (Endoscopy)
    Miami, Florida 33157, United States
  • Clarin Eye Care Center (OCT/Ophthalmoscopy)
    Miami, Florida 33176, United States
  • NSB Research
    New Smyrna Beach, Florida 32168, United States
  • IMIC Inc
    Palmetto Bay, Florida 33157, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Larkin Community Hospital (Endoscopy Procedure)
    South Miami, Florida 33143, United States
  • Absolute Surgical Specialists - Craig Amshel, MD
    Sun City Center, Florida 33573, United States
  • SimonMed Imaging
    Tampa, Florida 33069, United States
  • Perez Eye Center(OCT & Ophthalmoscopy only)
    Tampa, Florida 33603, United States
  • Tampa Bay Endoscopy Center(Proctosigmoidoscopy & colonoscopy ONLY)
    Tampa, Florida 33603, United States
  • Tampa Bay Endoscopy Center
    Tampa, Florida 33603, United States
  • Lyracore Health Alliance, Tampa Bay Pulmonology (PFT only)
    Tampa, Florida 33606, United States
  • Pulmonary and Sleep of Tampa Bay(PFT with DLCO only)
    Tampa, Florida 33607, United States
  • GCP Clinical Research,LLC
    Tampa, Florida 33609, United States
  • LoCicero Medical Group (PFT Procedure Only)
    Tampa, Florida 33609, United States
  • NewsomEye (OCT only)
    Tampa, Florida 33609, United States
  • South Tampa Surgery Center
    Tampa, Florida 33609, United States
  • GI Alliance (Patients Seen; IP Delivered)
    Gurnee, Illinois 60031, United States
  • Medical Eye Services LTD (Ophthalmoscopy with OCT)
    Gurnee, Illinois 60031, United States
  • North Shore Endoscopy Center (Endoscopy)
    Lake Bluff, Illinois 60044, United States
  • Libertyville Imaging Center (Diagnostic Imaging)
    Libertyville, Illinois 60048, United States
  • Chevy Chase Endoscopy Center (Endoscopy Facility Only)
    Chevy Chase, Maryland 20815, United States
  • Chevy Chase Pulmonary Associate (PFT Only)
    Chevy Chase, Maryland 20815, United States
  • Retina Group of Washington (Ophthalmoscopy and OCT Only)
    Chevy Chase, Maryland 20815, United States
  • Charter Radiology
    Columbia, Maryland 21044, United States
  • Cascades Endoscopy Center
    Columbia, Maryland 21045, United States
  • Gastro Center of Maryland, LLC
    Columbia, Maryland 21045, United States
  • Kaylani Eye Care ( Optical Coherence Tomography and Opthalmoscopy only)
    Hanover, Maryland 21076, United States
  • Lung Center (Pulmonary Function Test only)
    Laurel, Maryland 20707, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Advantage Diagnostics(X-Ray only)
    Beachwood, Ohio 44122, United States
  • Geauga Sleep Center(PFT only)
    Chardon, Ohio 44024, United States
  • UC Health Physicians Office
    Cincinnati, Ohio 45219, United States
  • UC Health (Pulmonary Function Testing)
    Cincinnati, Ohio 45229, United States
  • University of Cincinnati College of Medicine
    Cincinnati, Ohio 45267, United States
  • The Endoscopy Center of Lake County
    Mentor, Ohio 44060, United States
  • Vitreo Retinal Consultants(OCT only)
    Painesville, Ohio 44077, United States
  • Lake Pulmonary Associates (PFT only)
    Willoughby, Ohio 44094, United States
  • Retina Specialists of Ohio(OCT only)
    Willoughby Hills, Ohio 44094, United States
  • West Shore Endoscopy Center
    Camp Hill, Pennsylvania 17011, United States
  • Pulmonary and Critical Care Medicine Associates (PFT only)
    Harrisburg, Pennsylvania 17102, United States
  • Medical Arts Allergy,PC (PFT Only)
    Harrisburg, Pennsylvania 17109, United States
  • Farrel Opthalmology(OCT only)
    Harrisburg, Pennsylvania 17110, United States
  • Pinnacle Health Imaging at Tristan (X-Ray only)
    Harrisburg, Pennsylvania 17110, United States
  • Susquehanna Research Group
    Harrisburg, Pennsylvania 17110, United States
  • Harrisburg Eye Associates (OCT only)
    Harrisburg, Pennsylvania 17111, United States
  • Pulmonary and Critical Care Medicine Associates (PFT only)
    Lemoyne, Pennsylvania 17043, United States
  • Advanced Radiology Associates (x-Ray only)
    Edinburg, Texas 78539, United States

Showing the first 100 of 288 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Danese S, Goetsch M, Peyrin-Biroulet L, Yarur AJ, Dubinsky M, Rubin DT, Feagan BG, D'Haens G, Baert F, Lazin K, Gu G, Yu J, Lawendy N, Zang C, Wang W, Menon S, Law EH, Modesto I, Wosik K, Sidhu S, Niezychowski W, Vermeire S. The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial. Clin Gastroenterol Hepatol. 2026 Jun 4:S1542-3565(26)00405-2. doi: 10.1016/j.cgh.2026.05.024. Online ahead of print. PubMed 42248437 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jun 2024, 38 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 38 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2020
First posted
Oct 29, 2020
StartActual
Apr 12, 2021
Primary completionActual
Jun 19, 2024
CompletionActual
Jun 19, 2024
Results first posted
Jul 15, 2025
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04607837
Lead sponsor
Pfizer
Collaborators
Arena is a wholly owned subsidiary of Pfizer
Responsible party
Sponsor
First posted
Oct 29, 2020
Start date
Apr 12, 2021
Primary completion
Jun 19, 2024
Completion
Jun 19, 2024
Results posted
Jul 15, 2025
Last update
Jul 15, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion